Cite
HARVARD Citation
Connock, M. et al. (2020). Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert opinion on biological therapy. pp. 823-827. [Online].